140 likes | 153 Views
Explore opportunities for trainees from diverse backgrounds to promote diversity in health research, including grants, fellowships, and career development awards. Available at various career levels.
E N D
OPPORTUNITIES FOR TRAINEES TO PROMOTE DIVERSITYMarch 23, 2010 NSF Minority Faculty Development Workshop Alexis Bakos, PhD, MPH, RN,C Chief, Diversity Training Branch Center to Reduce Cancer Health Disparities, NCI
Continuing Umbrella of Research Experiences HS Undergrad Predoctoral Postdoctoral Junior Investigator NRSA Fellowships: F31 and T32 S R 0 1 Diversity Supplements R03 R21 Supplements to the CURE: SPORE: P50 Translational Cancer Center: P30 MD/POR R25T: Prevention and Control Cancer Center Grant: P30 Clinical Oncology Training Grants: K12 Career Development Career Awards K01 K08 K23 Transition Career: K22
Supplement Eligibility Eligible Individuals Ethnic and/or racial minorities Socio-economically disadvantaged groups First generation college graduates Individuals with disabilities Must be US Citizen or permanent resident Eligible Grants ■ NCI grants
Receipt of Supplement Applications by the NCI ■Application Receipt: Two Cycles ■ October 1 through December 1 ■ March 1 through May 1 ■Notice of Award: Office of Grants Administration
Research Supplements to Promote Diversity in Health Related Research ■Available for every career level e.g. High School through Junior faculty ■ Provides up to five years of support ■ * For T32, R25T, and K12 the supplement is awarded after slots are filled http://grants.nih.gov/grants/guide/pa-files/PA-08-190-html
Supplements to Promote Reentry into Biomedical and Behavioral Research Careers • Available for individuals who want to reestablish active research careers • Provides up to 3 years of support • Period of career interruption is 1 to 8 years • Candidate must have a doctoral degree • Support for salary, fringe benefits, supplies and travel http://grants.nih.gov/grants/guide/pa-files/PA-08-191.html
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research • Mechanism: R21 (PAR-09-162) • Purpose: To increase the diversity of the research workforce by supporting investigators from diverse populations in the area of basic cancer research. • Direct Cost: $275,000 for 2 years • Receipt Dates: Nov 23rd and June 23rd
Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities • Mechanism: R21 (PAR-09-160) • Purpose: To promote basic cancer research expertise in cancer health disparities • Direct Cost: $275,000 for 2 yrs • Receipt Date: Nov 23rd and June 23rd
Basic Cancer Research in Cancer Health Disparities • Mechanism: U01 (PAR-09-161) • Cooperative agreement FOA to conduct basic research into the causes and treatment of cancer health disparities • New methodologies • Secondary data analyses • Innovative mechanistic studies • $250,000/yr for up to 5 yrs • Receipt Date: Nov 23rd and June 23rd
Office of Technology & Industrial Relations (OTIR)Innovative Technology Development for Cancer Research • Mechanism R21 (RFA-CA-10-005) • Feasibility studies on early stage development (i.e., at their conceptual stage where feasibility has not been established) of cancer-relevant technologies in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities • Up to $500,000 over 3 yr period • Receipt Date: May 27 and Sept. 30, 2010
Office of Technology & Industrial Relations (OTIR)Application & Early Stage Development of Emerging Technology in Cancer Research • Mechanism: R21 (RFA-CA-10-003) • Feasibility studies on emerging cancer-relevant technologies (i.e., has passed the initial development stage but hasn’t been evaluated within the context of its intended use) in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities • Up to $275,000 direct costs over 2 yrs • Receipt Date: May 27 and Sept. 30, 2010
Office of Technology & Industrial Relations (OTIR)Innovative & Early-Stage Development of Emerging Technologies in Biospecimen Science • Mechanism R21 (RFA-CA-10-001) • Early stage studies that develop technologies capable of interrogating &/or maximizing the quality & utility of biospecimens • Up to $275,000 direct costs over 2 yrs • Receipt Date: May 27 and Sept. 30, 2010
■ Creates a pipeline of diverse cancer investigators ■ Investigators become mentors Example: Manuel Penichet, UCLA Recipient of: *Diversity Supplement *K award *R01s Manuel Penichet, M.D., Ph.D. Dr. Penichet and trainees
DTB Contacts • For Supplements • Peter Ogunbiyi: ogunbiyp@mail.nih.gov • For R21 & U01 Funding Opportunities • Anil Wali: walia@mail.nih.gov • For OTIR Funding Opportunities • LeeAnn Bailey: baileyl@mail.nih.gov Main Office: 301-496-7344